Development of anthrax DNA vaccines

Current Opinion in Molecular Therapeutics

Volumn 6, Issue 5, 2004, Pages 506-512

  Ferrari, Marilyn E ^a   Hermanson, Gary ^a   Rolland, Alain ^a  

^a VICAL INC   (United States)

Author keywords

Anthrax; Bacillus anthracis; DNA vaccine; Lethal factor; Lethal toxin; Plasmid based vaccine; Protective antigen

Indexed keywords

ANTHRAX VACCINE; B7 ANTIGEN; BETA 2 MICROGLOBULIN; CHOLESTEROL; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; DIOLEOYLPHOSPHATIDYLGLYCEROL; DNA VACCINE; DRUG CARRIER; FREUND ADJUVANT; GAG PROTEIN; GLYCOPROTEIN GP 140; HEMAGGLUTININ; HEPATITIS B SURFACE ANTIGEN; LIPID; MANNAN; N (2 HYDROXYETHYL) N,N DIMETHYL 2,3 BIS(TETRADECYLOXY) 1 PROPANAMINIUM BROMIDE; N (3 AMINOPROPYL) N,N DIMETHYL 2,3 BIS(MYRISTOLEYLOXY) 1 PROPANAMINIUM BROMIDE; NEF PROTEIN; NUCLEOPROTEIN; PLASMID DNA; PROTEIN SUBUNIT; RECOMBINANT PROTEIN; REV PROTEIN; THROMBOSPONDIN; TISSUE PLASMINOGEN ACTIVATOR; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VAXFECTIN; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN; ZINC ION;

ANTHRAX; BACILLUS ANTHRACIS; BACTERIAL STRAIN; BACTERIUM CULTURE; BIOLOGICAL WARFARE; CLINICAL TRIAL; DRUG FORMULATION; DRUG MANUFACTURE; DRUG MECHANISM; DRUG RESEARCH; DRUG SCREENING; GENE DELIVERY SYSTEM; GENE GUN; HISTORY OF MEDICINE; HUMAN; IMMUNOPATHOLOGY; INFECTION PREVENTION; LIVESTOCK; NONHUMAN; OCCUPATIONAL DISEASE; PATHOGENESIS; REVIEW; SUPERNATANT; TOXICITY;

ANIMALS; ANTHRAX; ANTHRAX VACCINES; BACILLUS ANTHRACIS; CLINICAL TRIALS, PHASE I; GENETIC VECTORS; HUMANS; VACCINES, DNA;

ANTHRAX; BACILLUS ANTHRACIS; BACTERIA (MICROORGANISMS);

EID: 6344278740     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Mock M, Fouet A: Anthrax. Annu Rev Microbiol (2001) 55:647-671.
2. Todar K: Bacillus anthracis and anthrax. In: Online Textbook of Bacteriology. University of Wisconsin-Madison, Madison, WI, USA (2001) (http://www.textbookofbacteriology.net/Anthrax.html
3. Dixon TC, Meselson M, Guillemin J, Hanna PC: Anthrax. N Engl J Med (1999) 341(11):815-826.
4. Inglesby TV, O'Toole T, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Friedlander AM, Gerberding J, Hauer J, Hughes J, McDade J et al: Anthrax as a biological weapon, 2002: Updated recommendations for management. J Am Med Assoc (2002) 287(17 ):2236-2252.
5. Hoffmaster AR, Ravel J, Rasko DA, Chapman GD, Chute MD, Marston CK, De BK, Sacchi CT, Fitzgerald C, Mayer LW, Maiden MC et al. Identification of anthrax toxin genes in a Bacillus cereus associated with an illness resembling inhalation anthrax. Proc Natl Acad Sci USA (2004) 101(22):8449-8454.
6. Mock M, Mignot T: Anthrax toxins and the host: A story of intimacy. Cell Microbiol (2003) 5(1): 15-23.
7. Bradley KA, Mogridge J, Mourez M, Collier RJ, Young JA: Identification of the cellular receptor for anthrax toxin. Nature (2001) 414(6860):225-229.
8. Klimpel KR, Molloy SS, Thomas G, Leppla SH: Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin. Proc Natl Acad Sci USA (1992) 89(21):10277-10281.
9. Singh Y, Ghaudhary VK, Leppla SH: A deleted variant of Bacillus anthracis protective antigen is non-toxic and blocks anthrax toxin action in vivo. J Biol Chem (1989) 264 32):19103-19107.
10. Mogridge J, Cunningham K, Lacy DB, Mourez M, Collier RJ: The lethal and edema factors of anthrax toxin bind only to oligomeric forms of the protective antigen. Proc Natl Acad Sci USA (2002) 99(10):7045-7048.
11. Duesbery NS, Webb CP, Leppla SH, Gordon VM, Klimpel KR, Copeland TD, Ahn NG, Oskarsson MK, Fukasawa K, Paull KD, Vande Woude GF: Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science (1998) 280(5364):734-737.
12. Moayeri M, Haines D, Young HA, Leppla SH: Bacillus anthracis lethal toxin induces TNF-α-independent hypoxia-mediated toxicity in mice. J Clin Invest (2003) 112(5):670-682.
13. Tigertt WD: Anthrax. William Smith Greenfield, M.D., F.R.C.P., Professor Superintendent, the Brown Animal Sanatory Institution (1878-81). Concerning the priority due to him for the production of the first vaccine against anthrax. J Hyg (Lond) (1980) 85 3):415-420.
14. Friedlander AM, Welkos SL, Ivins BE: Anthrax vaccines. Curr Top Microbiol Immunol (2002) 271:33-60.
15. Brachman PS, Adimora AA, Berry SH, Bush T, Eickhoff TC, Ferrieri P, Gotschlich EC, Hilleman M, Kasper DL, Lockshin MD, Madigan D et al: An Assessment of the CDC Anthrax Vaccine Safety and Efficacy Research Program. The National Academies Press, Washington, DC, USA (2003) (http://www.nap.edu/books/0309086264/html/).
16. Turnbull PC, Leppla SH, Broster MG, Quinn CP, Melling J: Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Med Microbiol Immunol (1988 177 5):293-303.
17. Wiesen AR, Littell CT: Relationship between prepregnancy anthrax vaccination and pregnancy and birth outcomes among US Army women. J Am Med Assoc (2002) 287(12):1556-1560.
18. Joellenbeck L, Zwanziger LL, Durch JS, Strom BL: The Anthrax Vaccine, is it Safe? Does it Work? The National Academies Press, Washington, DC, USA (2002) (http://www.nap.edu/books/0309083095/html/).
19. Jernigan DB, Raghunathan PL, Bell BP, Brechner R, Bresnitz EA, Butler JC, Cetron M, Cohen M, Doyle T, Fischer M, Greene C et al Investigation of bioterrorism-related anthrax, United States, 2001: Epidemiologic findings. Emerging Infect Dis (2002) 8 10):1019-1028.
20. National Institute of Allergy and Infectious Diseases: NIAID Biodefense Research. World Wide Web Site (http://www2.niaid.nih.gov/biodefense/).
21. Office of Extramural Research at the National Institutes of Health: Computer Retrieval of Information on Scientific Projects. World Wide Web Site (http://crisp.cit.nih.gov/).
22. Ivins BE, Pitt ML, Fellows PF, Farchaus JW, Benner GE, Waag DM, Little SF, Anderson GW Jr, Gibbs PH, Friedlander AM: Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine (1998) 16 11-12):1141-1148.
23. Filmore D: Taking care of biosecurity business. Modern Drug Discovery (2004) 7:36-42.
24. Donnelly JJ, Ulmer JB, Liu MA: DNA vaccines. Dev Biol Stand (1998) 95:43-53.
25. Gu ML, Leppla SH, Klinman DM: Protection against anthrax toxin by vaccination with a DNA plasmid encoding anthrax protective antigen. Vaccine (1999) 17(4):340-344.
26. Williamson ED, Beedham RJ, Bennett AM, Perkins SD, Miller J, Baillie LW: Presentation of protective antigen to the mouse immune system: Immune sequelae. J Appl Microbiol (1999) 87 2):315-317.
27. Boyle JS, Koniaras C, Lew AM: Influence of cellular location of expressed antigen on the efficacy of DNA vaccination: Cytotoxic T lymphocyte and antibody responses are suboptimal when antigen is cytoplasmic after intramuscular DNA immunization. Int Immunol (1997) 9(12):1897-1906.
28. Price BM, Liner AL, Park S, Leppla SH, Mateczun A, Galloway DR: Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein. Infect Immun (2001) 69(7):4509-4515.
29. Galloway D, Liner A, Legutki J, Mateczun A, Barnewall R, Estep J: Genetic immunization against anthrax. Vaccine (2004) 22(13-14):1604-1608.
30. Goldenthal KL: Prospective on the proposed rule. World Wide Web Site (2004) (www.fda.gov/cber/summaries/120600bio19KG.ppt).
31. Hedstrom RC, Doolan DL, Wang R, Gardner MJ, Kumar A, Sedegah M, Gramzinski RA, Sacci JB Jr, Charoenvit Y, Weiss WR, Margalith M et al: The development of a multivalent DNA vaccine for malaria. Springer Semin Immunopathol (1997) 19(2):147-159.
32. Riemenschneider J, Garrison A, Geisbert J, Jahrling P, Hevey M, Negley D, Schmaljohn A, Lee J, Hart MK, Vanderzanden L, Custer D et al: Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. Vaccine (2003) 21(25-26):4071-4080.
33. Payne LG, Fuller DH, Haynes JR: Particle-mediated DNA vaccination of mice, monkeys and men: Looking beyond the dogma. Curr Opin Mol Ther (2002) 4(5):459-466.
34. Roy MJ, Wu MS, Barr LJ, Fuller JT, Tussey LG, Speller S, Culp J, Burkholder JK, Swain WF, Dixon RM, Widera G et al: Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine (2000) 19(7-8):764-778.
35. Tucker SN, Lin K, Stevens S, Scollay R, Bennett MJ, Olson DC: Systemic and mucosal antibody responses following retroductal gene transfer to the salivary gland. Mol Ther (2003) 8 3):392-399.
36. Fischer L, Minke J, Dufay N, Baudu P, Audonnet JC: Rabies DNA vaccine in the horse: Strategies to improve serological responses. Vaccine (2003) 21(31):4593-4596.
37. Hermanson G, Whitlow V, Parker S, Tonsky K, Rusalov D, Ferrari M, Lalor P, Komai M, Mere R, Bell M, Brenneman K et al: A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. Proc Natl Acad Sci USA (2004) 101(37):13601-13606.
38. Wang R, Doolan DL, Le TP, Hedstrom RC, Coonan KM, Charoenvit Y, Jones TR, Hobart P, Margalith M, Ng J, Weiss WR et al: Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science (1998) 282(5388):476-480.
39. Hartikka J, Bozoukova V, Ferrari M, Sukhu L, Enas J, Sawdey M, Wloch MK, Tonsky K, Norman J, Manthorpe M, Wheeler CJ: Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens. Vaccine (2001) 19(15-16):1911-1923.
40. Reyes L, Hartikka J, Bozoukova V, Sukhu L, Nishioka W, Singh G, Ferrari M, Enas J, Wheeler CJ, Manthorpe M, Wloch MK et al: Vaxfectin enhances antigen specific antibody titers and maintains Th1 type immune responses to plasmid DNA immunization. Vaccine (2001) 19(27):3778-3786.
41. Nukuzuma C, Ajiro N, Wheeler CJ, Konishi E: Enhancing effect of vaxfectin on the ability of a Japanese encephalitis DNA vaccine to induce neutralizing antibody in mice. Viral Immunol (2003) 16(2):183-189.
42. Locher CP, Witt SA, Ashlock BM, Levy JA: Evaluation of genetic immunization adjuvants to improve the effectiveness of a human immunodeficiency virus type 2 (HIV-2) envelope DNA vaccine. DNA Cell Biol (2004) 23(2):107-110.
43. Locher CP, Witt SA, Ashlock BM, Polacino P, Hu SL, Shiboski S, Schmidt AM, Agy MB, Anderson DM, Staprans SI, zur Megede J, Levy JA: Human immunodeficiency virus type 2 DNA vaccine provides partial protection from acute baboon infection. Vaccine (2004) 22 17-18):2261-2272.
44. Sankar V, Baccaglini L, Sawdey M, Wheeler CJ, Pillemer SR, Baum BJ, Atkinson JC: Salivary gland delivery of pDNA-cationic lipoplexes elicits systemic immune responses. Oral Dis (2002) 8(6):275-281.
45. D'Souza S, Rosseels V, Denis O, Tanghe A, De Smet N, Jurion F, Palfliet K, Castiglioni N, Vanonckelen A, Wheeler C, Huygen K et al Improved tuberculosis DNA vaccines by formulation in cationic lipids. Infect Immun (2002) 70(7):3681-3688.
46. Fischer L, Tronel JP, Minke J, Barzu S, Baudu P, Audonnet JC: Vaccination of puppies with a lipid-formulated plasmid vaccine protects against a severe canine distemper virus challenge. Vaccine (2003) 21(11-12):1099-1102.
47. Jiao X, Wang RY, Feng Z, Alter HJ, Shih JW: Modulation of cellular immune response against hepatitis C virus nonstructural protein 3 by cationic liposome encapsulated DNA immunization. Hepatology (2003) 37(2):452-460.
48. Ishii N, Fukushima J, Kaneko T, Okada E, Tani K, Tanaka SI, Hamajima K, Xin KQ, Kawamoto S, Koff W, Nishioka K et al: Cationic liposomes are a strong adjuvant for a DNA vaccine of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (1997) 13(16):1421-1428.
49. Okada E, Sasaki S, Ishii N, Aoki I, Yasuda T, Nishioka K, Fukushima J, Miyazaki J, Wahren B, Okuda K: Intranasal immunization of a DNA vaccine with IL-12- and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens. J Immunol(1997) 159(7):3638-3647.
50. Toda S, Ishii N, Okada E, Kusakabe KI, Arai H, Hamajima K, Gorai I, Nishioka K, Okuda K: HIV-1-specific cell-mediated immune responses induced by DNA vaccination were enhanced by mannan-coated liposomes and inhibited by anti-interferon-γ antibody. Immunology (1997) 92 (1): 111-117.
51. Yokoyama M, Zhang J, Whitton JL: DNA immunization: Effects of vehicle and route of administration on the induction of protective antiviral immunity. FEMS Immunol Med Microbiol (1996) 14 4):221-230.
52. Gramzinski RA, Millan CL, Obaldia N, Hoffman SL, Davis HL: Immune response to a hepatitis B DNA vaccine in Aotus monkeys: A comparison of vaccine formulation, route, and method of administration. Mol Med (1998) 4(2):109-118.
53. Perrie Y, Frederik PM, Gregoriadis G: Liposome-mediated DNA vaccination: The effect of vesicle composition. Vaccine (2001) 19(23-24):3301-3310.
54. Wong JP, Zabielski MA, Schmaltz FL, Brownlee GG, Bussey LA, Marshall K, Borralho T, Nagata LP: DNA vaccination against respiratory influenza virus infection. Vaccine (2001) 19 17-19):2461-2467.
55. Sha Z, Vincent MJ, Compans RW: Enhancement of mucosal immune responses to the influenza virus HA protein by alternative approaches to DNA immunization. Immunobiology (1999) 200 1):21-30.